Since the mRNA expression levels of sclerostin in liver tissues were extraordinarily low (data are not shown), when compared with the expression levels of sclerostin in bone tissues, it was speculated that the decreased sclerostin levels in NAFLD subjects may mainly reflect reduced sclerostin secretion from bone tissues. Here, SOST is linked to metabolic dysfunction-associated steatotic liver disease.